News

RBP-6000 is an investigational buprenorphine sustained-release formulation, which uses the company’s Atrigel delivery system Indivior said if granted marketing authorization in the US, the drug will provide a

The most significant is new technology for Direct Clinical Document Architecture (CDA) Automation of reporting to the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network

The Foam Assets include US rights to Fabior and Sorilux, Canadian rights to Luxiq® and Olux-E® and Mexican rights to betamethasone foam. Under the terms of the agreement

The collaboration, facilitated by Johnson & Johnson Innovation, is focused on further understanding applications of Xycrobe's platform technology developed for the treatment of inflammatory skin diseases. The planned

The phase III program is evaluating a two-drug regimen of dolutegravir (Tivicay) and lamivudine (Epivir) on about 1,400 men and women across the world versus the three-drug regimen

The study being terminated involved patients with one copy of the F508del mutation and one copy of a mutation that results in minimal cystic fibrosis transmembrane conductance regulator

NeuroVive now holds approximately 10 percent of the shares in Isomerase. The overall aim with the acquisition is to strengthen the existing partnership and accelerate NeuroVive’s research and

These data further support the efficacy of BAREMSIS which has previously been shown to prevent PONV alone, and in combination with standard anti-emetics in pivotal Phase 3 prophylaxis

The Company plans to continue collecting and analyzing epidemiological data relating to OPANA ER. Endo's financial projections for 2016 did not assume approval of the sNDA. Endo executive